Flagship’s Valo seeks cancer-like approach to CV drug development with G3 partnership

Valo’s partnership with G3 sheds more light on the Flagship Pioneering-built company’s in silico target discovery strategy, which the companies think will also identify new subtypes of disease.

Valo Health LLC, which emerged from stealth in September, raised a $96.5 million series A round last year to develop an R&D pipeline based on its Opal computational platform. Using Opal, company is analyzing human data to identify molecular targets and biomarkers for cancer, neurodegeneration and cardiometabolic diseases...